Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis

Archives of Ophthalmology

Volumn 121, Issue 9, 2003, Pages 1229-1233

  Wilhelmus, Kirk R ^a,c   Abshire, Robert L ^b   Schlech, Barry A ^b  

^a CULLEN EYE INSTITUTE   (United States)

^b ALCON RESEARCH LTD   (United States)

^c Department of Ophthalmology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; EYE OINTMENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; EYE DROPS;

ADULT; ARTICLE; BACTERIAL KERATITIS; BACTERIUM CULTURE; BIOMICROSCOPY; COHORT ANALYSIS; CORNEA; DIAGNOSTIC TEST; DRUG RESPONSE; DRUG SCREENING; DRUG SENSITIVITY; EPITHELIZATION; FEMALE; HUMAN; IN VITRO STUDY; ISOLATION PROCEDURE; KERATITIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SLIT LAMP; TREATMENT OUTCOME; ANTIBIOTIC RESISTANCE; BACTERIAL EYE INFECTION; BACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA ULCER; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; OINTMENT; RANDOMIZED CONTROLLED TRIAL;

ANTI-INFECTIVE AGENTS; BACTERIA; CIPROFLOXACIN; CORNEA; CORNEAL ULCER; DRUG RESISTANCE, BACTERIAL; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OINTMENTS; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES;

EID: 0141499075     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.121.9.1229     Document Type: Article

References (62)

1. Erie JC, Nevitt MP, Hodge DO, Ballard MJ. Incidence of ulcerative keratitis in a defined population from 1950 through 1988. Arch Ophthalmol. 1993;111:1665-1671.
2. Gonzales CA, Srinivasan M, Whitcher JP, Smolin GS. Incidence of corneal ulceration in Madurai District, south India. Ophthalmic Epidemiol. 1996;3:159-166.
3. Davis R, Markham A, Balfour JA. Ciprofloxacin: an updated review of its pharmacology, therapeutic efficacy, and tolerability. Drugs. 1996;51:1019-1074.
4. McLeod SD, DeBacker CM, Viana MA. Differential care of corneal ulcers in the community based on apparent severity. Ophthalmology. 1996;103:479-484.
5. Forster RK. Conrad Berens lecture: the management of infectious keratitis as we approach the 21st century. CLAO J. 1998;24:175-180.
6. Smith A, Pennefather PM, Kaye SB, Hart CA. Fluoroquinolones: place in ocular therapy. Drugs. 2001;61:747-761.
7. Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis. 2001;32(suppl 1):S9-S15.
8. Ogawa GSH, Hyndiuk RA. The fluoroquinolones: new antibiotics in ophthalmology. Int Ophthalmol Clin. 1993;33:59-68.
9. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol. 1991;112(suppl):34-47.
10. Wilhelmus KR, Hyndiuk RA, Caldwell DR, Abshire RL, Folkens AT, Godio LB. 0.3% Ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. Arch Ophthatmol 1993;111:1210-1218.
11. Hyndiuk RA, Eiferman RA, Caldwell DR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ophthalmology. 1996;103:1854-1863.
12. Kosrirukvongs P, Buranapongs W. Topical ciprofloxacin for bacterial corneal ulcer. J Med Assoc Thailand. 2000;93:776-782.
13. Snyder MW, Katz HR. Ciprofloxacin-resistant bacterial keratitis. Am J Ophthalmol. 1992;114:336-338.
14. Maffett M, O'Day DM. Ciprofloxacin-resistant bacterial keratitis. Am J Ophthalmol. 1993;115:545-546.
15. Knauf HP, Silvany R, Southern PMJ, Risser RC, Wilson SE. Susceptibility of corneal and conjunctival pathogens to ciprofloxacin. Cornea. 1996;15:66-71.
16. Wilhelmus KR, Penland RL. Emerging resistance among ocular isolates of gram-positive cocci [abstract]. Invest Ophthalmol Vis Sci. 1996;37(suppl):S877.
17. Chaudhry NA, Flynn HW Jr, Murray TG, Tabandeh H, Mello MO Jr, Miller DR. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 1999;128:509-510.
18. Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptiblity of bacterial keratitis pathogens to ciprofloxacin: emerging resistance. Ophthalmology. 1999;106:80-85.
19. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a five-year review. Ophthalmology. 1999;106:1313-1318.
20. Garg P, Sharma S, Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology. 1999;106:1319-1323.
21. Pinna A, Zanetti S, Sotgui M, Sechi LA, Fadda G, Carta F. Identification and antibiotic susceptibility of coagulase-negative staphylococci in cornea/external infections. Br J Ophthalmol. 2000;83:771-773.
22. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497-1502.
23. Bharathi MJ, Ramakrishnan R, Vasu S, Meenakshi R, Palaniappan R. In-vitro efficacy of antibacterials against bacterial isolates from corneal ulcers. Indian J Ophthalmol. 2002;50:109-114.
24. Díaz Valle D, Alós Cortés JI, Arteaga Sánchez A, Toledano Fernández N, Poza Morales Y, Diaz-Valle T. Absceso corneal por Pseudomonas aeruginosa resistente a fluoroquinolonas. Arch Soc Esp Oftalmol. 2002;77:397-399.
25. Parmar P, Salman A, Kalavathy CM, Jesudasan CA, Thomas PA. Pneumococcal keratitis: a clinical profile. Clin Experiment Ophthalmol. 2003;31:44-47.
26. Wilhelmus KR, Liesegang TJ, Osato MS, Jones DB. Cumitech 13A. Laboratory Diagnosis of Ocular Infections. Washington, DC: American Society for Microbiology; 1994.
27. McDonnell PJ. Empirical or culture-guided therapy for microbial keratitis? a plea for data. Arch Ophthalmol. 1996;114:84-87.
28. Pepose JS, Wilhelmus KR. Divergent approaches to the management of corneal ulcers. Am J Ophthalmol. 1992;114:630-632.
29. McLeod SD, Kolahdauz-lsfahani A, Rostamiam K, Flowers CW, Lee PP, McDonnell PJ. The role of smears, cultures, and antibiotic susceptibility testing in the management of suspected infectious keratitis. Ophthalmology. 1996;103:23-28.
30. Kowal VO, Levey SB, Laibson PR, Rapuano CJ, Cohen EJ. Use of routine antibiotic sensitivity testing for the management of corneal ulcers. Arch Ophthalmol. 1997;115:462-465.
31. Levey SB, Katz HR, Abrams DA, Hirschbein MJ, Marsh MJ. The role of cultures in the management of ulcerative keratitis. Cornea. 1997;16:383-386.
32. Rodman RC, Spisak S, Sugar A, Meyer RF, Soong HK, Musch DC. The utility of culturing corneal ulcers in a tertiary referral center versus a general ophthalmology clinic. Ophthalmology. 1997;104:1897-1901.
33. Morlet N, Dart J. Routine antibiotic sensitivity testing for corneal ulcers. Arch Ophthalmol. 1998;116:1262.
34. Gritz DC, Whitcher JP Jr. Topical issues in the treatment of bacterial keratitis. Int Ophthalmol Clin. 1998;38:107-114.
35. Jorgensen JH, Turnidge JD, Washington JA. Antibacterial susceptibility tests: dilution and disk diffusion methods. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. 7th ed. Herndon, Va: ASM Press; 1999:1526-1543.
36. National Committee for Clinical Laboratory Standards. Approved Standard Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Vol 20. 5th ed. Villanova, Pa: National Committee for Clinical Laboratory Standards; 2000. No. 2. Publication M7-A5.
37. National Committee for Clinical Laboratory Standards. Informational Supplement: Performance Standards for Antimicrobial Susceptibility Testing. Vol 21. 11th ed. Villanova, Pa: National Committee for Clinical Laboratory Standards; 2001. Publication M100-S11.
38. Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika. 1981;68:373-379.
39. Scharfstein D, Robins JM, Eddings W, Rotnitzky A. Inference in randomized studies with informative censoring and discrete time-to-event endpoints. Biometrics. 2001;57:404-413.
40. Rotinzky A, Scharfstein D, Su T-L, Robins J. Methods for conducting sensitivity analysis of trials with potentially ignorable competing causes of censoring. Biometrics. 2001;57:103-113.
41. StataCorp. Stata Statistical Software: Release 8. College Station, Tex: Stata Corp; 2003.
42. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for non-uniform patient entry, losses to follow-up, noncompliance and stratification. Biometrics. 1986;42:507-519.
43. Morlet N, Minassian D, Butcher J. Risk factors for treatment outcome of suspected microbial keratitis. Br J Ophthalmol. 1999;83:1027-1031.
44. Public and Scientific Affairs Board, American Society for Microbiology. Report of the ASM Task Force on Antibiotic Resistance. Antimicrob Agents Chemother. 1995;suppl:1-23.
45. Interagency Task Force on Antimicrobial Resistance. A Public Health Action Plan to Combat Antimicrobial Resistance. Washington, DC: US Dept of Health and Human Services; 2001.
46. Bishara J, Leibovici L, Huminer D, et al. Five-year prospective study of bacteremic urinary tract infection in a single institution. Eur J Clin Microbiol Infect Dis. 1997;16:563-567.
47. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med. 1998;244:379-386.
48. McLeod SD, LaBree LD, Tayyanipour R, Flowers CW, Lee PP, McDonnell PJ. The importance of initial management in the treatment of severe infectious corneal ulcers. Ophthalmology. 1995;102:1943-1948.
49. Turnidge JD, Jorgensen JH. Antimicrobial susceptibility testing: general considerations. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. 7th ed. Washington, DC: ASM Press; 1999:1469-1473.
50. Murray PR. Antimicrobial susceptibility tests: testing methods and interpretive problems. In: Poupard JA, Walsh LR, Kleger B, eds. Antimicrobial Susceptibility Testing: Critical Issues for the 90s. New York, NY: Plenum Press; 1994:15-25.
51. Johnson CC. In vitro testing: correlations of bacterial susceptibility. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Philadelphia, Pa: Williams & Wilkins; 1996:813-834.
52. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother. 2000;46:669-683.
53. Lorian V, Burns L. Predictive value of susceptibility tests for the outcome of antibacterial therapy. J Antimicrob Chemother. 1990;25:175-181.
54. Kowalski RP, Karenchak LM, Gordon YJ. Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels. Cornea. 1998;17:282-287.
55. Drusano GL. Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome. J Chemother. 2000;12(suppl 4): 21-26.
56. Jones DB. A plan for antimicrobial therapy in bacterial keratitis. Trans Am Acad Ophthalmol Otolaryngol. 1975;79:95-103.
57. Kowalski RP, Pandya AN, Karenchak LM, et al. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. Ophthalmology. 2001;108:1826-1829.
58. McDonnell PJ, Nobe J, Gauderman WJ, Lee P, Aiello A, Trousdale M. Community care of corneal ulcers. Am J Ophthalmol. 1992;114:531-538.
59. Coster DJ, Badenoch PR. Host, microbial, and pharmacological factors affecting the outcome of suppurative keratitis. Br J Ophthalmol. 1987;71:96-101.
60. Blanton CL, Rapuano CJ, Cohen EJ, Laibson PR. Initial treatment of microbial keratitis. CLAO J. 1996;22:136-140.
61. Kim RY, Cooper KL, Kelly LD. Predictive factors for response to medical therapy in bacterial ulcerative keratitis. Graefes Arch Clin Exp Ophthalmol. 1996;234:731-738.
62. Jones DB. Emerging antibiotic resistance: real and relative. Arch Ophthalmol. 1996;114:91-92.